Dr. Kim Kuypers and Natasha Mason were invited to speak at and participate in an event in Helsinki, Finland, discussing research on the therapeutic potential and mechanisms of action of psilocybin and MDMA. The panel discussion has now been posted, and can be viewed here.
Most street cannabis contains large quantities of THC, the chemical in cannabis that gets people ‘high’, but there is increasing use of medicinal products that also contain CBD, a non-intoxicating cannabinoid with promising therapeutically potential. It has often been proposed that administering CBD may reduce some of the impairment caused by THC. To test this,… Continue reading Cannabidiol (CBD) content in vaporized cannabis does not prevent tetrahydrocannabinol (THC)-induced impairment of driving and cognition.
Pint of Science is coming to the Netherlands this year, and we will be sharing some of our research! If you are in the Maastricht area on May 20th, come to Cafe Charlemagne to hear about "the good, the bad, and the intoxicated". For full event info, check out the website.
New study from our group assessed cognitive and subjective effects of a synthetic cannabinoid, JWH-018. Read coverage of the publication from Live Science.
After many years of animal research, in which we found that inhibition of the enzyme phosphodiesterase type 4 (PDE4) improved memory in animals, we now find first evidence that this mechanism also works in humans. In this study, we tested how many words older participants (aged between 60 and 85 years old) could remember from… Continue reading Acute treatment with the PDE4 inhibitor roflumilast improves verbal word memory in healthy old individuals: a double-blind placebo-controlled study